

## Healthcare REITs

Healthcare earnings recap weeks 2&3:  
WELL, VTR, & MPW

Price Objective Change

**WELL: Two underappreciated aspects of 4Q results**

Two key takes from WELL's 4Q results: (1) occupancy growth accelerated across a seasonally soft quarter and into January and (2) WELL acquired a roughly \$1B portfolio of Wellness Housing (55+ housing). On the first point, we view this as a sign that improving demographics are beginning to show up in results. On the latter, we believe investors are underappreciating the opportunity set that WELL has within Wellness housing. We believe Wellness Housing will become the third pillar of WELL's business in the years ahead. We reiterate Buy on WELL.

**VTR underwhelms again but SH is a strong tailwind**

The main debate after VTR's 4Q results and initial 2024 guide is whether or not management provided a conservative guide. After speaking with management we believe the main area of conservatism is within the interest expense guide. The rest of the guide appears to be realistic. We have lowered our growth trajectory in the out years. Our revised 2025 AFFO growth is 5.1% (previously: 11.1% and the Street's 2.9%). We reiterate Buy given VTR's senior housing (SH) exposure.

**MPW: the road ahead remains tough; reiterate U/P**

We reiterate Underperform on MPW. We remain concerned about MPW's dividend. Management flagged that asset sales will be the key to covering the dividend. "The dividend is not dependent on Steward's rent. It's more dependent on our ability to close some of these liquidity transactions." We are uncertain about MPW's ability to close on dispositions in a timely manner given prior delays in asset sales and the capital market backdrop. We assume a 25% cut to the dividend. In addition, there are concerns on the health of Steward (top tenant) which was moved to a cash basis as it struggles to pay rent.

**PO and estimate changes following 4Q23 earnings**

After updating our model for 4Q23 earnings and 2024 guide, we are lowering our PO for VTR to \$49 from \$53. We derive our PO from applying a AFFO multiple of 20x (previously 20.5x) to our 2024E AFFO estimate of \$2.44 (previously \$2.52). We believe the multiple is warranted given current market conditions. Also, after updating for 4Q23 earnings, we are lowering our PO for MPW to \$4.05 (previously \$5.00). Our PO trades in line with our forward NAV. We derive our NAV by applying a 9.5% (unchanged) cap rate to our forward NOI of \$991M.

26 February 2024

Equity  
United States  
REITs

**Joshua Dennerlein**  
Research Analyst  
BofAS  
+1 646 855 1681  
[joshua.dennerlein@bofa.com](mailto:joshua.dennerlein@bofa.com)

**Jeffrey Spector**  
Research Analyst  
BofAS  
+1 646 855 1363  
[jeff.spector@bofa.com](mailto:jeff.spector@bofa.com)

**Farrell Granath**  
Research Analyst  
BofAS  
+1 646 855 1351  
[farrell.granath@bofa.com](mailto:farrell.granath@bofa.com)

**REITs Team**  
BofAS

[See Team Page for List of Analysts](#)

**Exhibit 1: Summary of PO changes**

Updated price objective after review of models

Ticker	Old PO	New PO	QRQ	Price
VTR	\$53.00	\$49.00	B-1-7	\$44.16
MPW	\$5.00	\$4.05	C-3-8	\$3.84

**Source:** BofA Global Research, prices as of 2/23/2024

BofA GLOBAL RESEARCH

See inside for Key terms

For more details see [our Healthcare REIT primer here](#).

**BofA Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Refer to important disclosures on page 17 to 19. Analyst Certification on page 15. Price Objective Basis/Risk on page 14.**

12663678

Timestamp: 26 February 2024 07:53AM EST

# Contents

Key comments from the earnings calls	3
Leverage	12
PO & Estimate changes	12
Key terms:	13
Research Analysts	20

# Key comments from the earnings calls

## WELL key quotes from the earnings call on 2/14

- **Occupancy growth:** "In terms of our senior housing operating portfolio, I was particularly encouraged by the occupancy growth in fourth quarter, which is seasonally not the strongest period. The portfolio saw 110 basis points of sequential occupancy gains, which translate into 330 basis points year-over-year occupancy growth. And the 330 basis points year-over-year occupancy growth is by far the highest level we have ever achieved in the fourth quarter of any year in our recorded history. Just as compelling is that looking at the intra-quarter trends year-over-year occupancy growth strengthened each month, which is unusual given the aforementioned seasonality of the business."
- **Acquisition pace:** "The torrid pace of investment activity in Q4 has continued with 2024 starting off with a bang. In fact, I do not recall having ever been this busy in first quarter on the deal front."
- **RevPOR and ExpPOR:** "The 23.7% fourth quarter year-over-year NOI increase in our same-store housing operating portfolio was a function of 9.7% revenue growth driven by the combination of 5.5% RevPOR growth and 330 basis points of average occupancy gains and moderating expense growth. Expenses remain in control, coming in at 5.7% for the quarter over the prior year's quarter. The strong revenue growth and expense control led to continued margin expansion of 290 basis points. Again our ExpPOR growth for the quarter set a record for the lowest growth in recorded history at 1.7%. All three regions continue to show strong same-store revenue growth starting with the US at 9.4%, Canada and the UK growing at 9.7% and 14.1% respectively. The strong revenue growth in each region, combined with the expense control have led to fantastic NOI growth in the US, Canada and the UK of 21.8%, 21.7% and 75.5% respectively."
- **Integra portfolio update:** "I am also excited to provide an update on the performance of our Integra portfolio, where we have continued to see a sequential improvement in performance. The 140 building, that first transition to regional operators. We have seen annualized EBITDARM improve by more than \$300 million, from losing more than \$85 million in the three months prior to the transition to positive \$228 million in the third quarter. While there continues to be meaningful remaining upside in performance beyond the current state I am pleased to announce that EBITDARM coverage is now greater than 1.5 times."
- **4Q23 investments:** "By acquiring these assets at an attractive basis and consolidating operations under the same operator, we are able to reap the operating benefits of regional density. In the fourth quarter alone, we closed on nearly \$3 billion of investments while remaining targeted and disciplined. We acquired 44 senior housing properties from 11 different sellers growing our relationship with seven existing operating partners. We acquired roughly 8,800 units with an average age of around seven years at an average basis of \$222,000 per unit and approximately 40% discount to replacement cost. These transactions have a low 6s year-one yield and are expected to generate unlevered IRRs, north of 10%."
- **Affinity Living Communities:** "Looking ahead to 2024, we are off to an exciting start. We are delighted to announce our strategic partnership with Affinity Living communities in which we are entering into a long-term programmatic development relationship and acquiring the Affinity portfolio of 25 active adult properties with an average age of less than eight years for \$969 million or \$233,000 per unit after allocating the NPV of interest cost-savings to the assumed below-market debt."



- **2024 FFO Guidance:** “We introduced an initial full-year 2024 outlook for net income attributable to common stockholders of \$1.21 to \$1.37 per diluted share and normalized FFO of \$3.94 to \$4.10 per diluted share, or \$4.02 at the midpoint. As mentioned in our release last night, our 2024 guidance contemplates no HHS or other government grants. So after adjusting for \$0.03 received in 2023, the midpoint of our initial guidance represents 11.5% year-over-year growth.”
- **Double digit NOI growth:** “We should have double-digit NOI growth for years to come. I hope that sort of answers your question. We have no hubris of sort of knowing what we don't know, but we think is also this idea that because our business has done so well for last two years, it has to go down, it has to meaningfully decelerate. It sort of reminds me that perhaps we should have more humility of what we don't know. We'll see how it plays out, we'll see what market gives us.”
- **Expectations of growth going forward:** “But if you look at all other industry data that you will see our portfolio has meaningfully outperformed both in rate growth as well as occupancy growth, but what's new about that? But you can probably look at the NIC data and others and decide that they get to that point. But as I said, we don't know what the future will give us. What we endeavor what our promise to you that will put 200 person effort to outperform the market and that's what we're trying to do. And so far what I've seen, I mean, John mentioned a stat that if we do achieve our NOI growth guidance in the SHO portfolio this year. There is no guarantee we will, but if we do that will be 75% compounded growth over three years. There is-- I don't believe there's any precedents of that in a large, broad sort of your portfolio. So we are meaningfully outperforming the market and that gap is widening and I think it will continue to widen.”
- **Double digit revenue growth:** “We'll see how this plays out, but we think, it's our guests as we sit here today and nothing but a guess that will be largely in the same ballpark up close to double-digit revenue growth that we have seen last year.”

## VTR – key quotes from the earnings call on 2/15

- **2024 earnings guidance:** “Notably, our projected 2024 normalized FFO growth of 5% per share puts us in the top 20% of all REITs that have issued guidance to-date. In 2024, we expect to benefit from steady growth from our outpatient medical research and triple-net lease portfolios. As we look into 2025, we have two large lease renewals, one with Brookdale and Senior Housing and another with Kindred for a portion of our LTAC.”
- **Brookdale and Kindred comments:** “In Brookdale's case, our communities are enjoying positive operating trends and they have significant net absorption potential. In Kindred situation, rent coverage remains challenged and it's too early to say what the ultimate outcome in 2025 will be. Kindred remains focused on performance improvements that could benefit 2024 and 2025 financial results. In all cases, we are fully prepared to maximize NOI over time.”
- **Positive SHOP growth:** “In SHOP, January is already starting positively with 200 basis points of year-over-year same-store occupancy growth. In 2024, we expect year-over-year normalized FFO and SHOP same-store cash NOI growth to accelerate in the second half with a SHOP NOI exit run rate that should support continued SHOP growth in 2025 and beyond.”
- **Double digit SHOP growth:** “Looking forward to 2024. We are excited to continue on our multi-year growth trajectory as we are expecting our third consecutive year of double-digit NOI growth in our same-store SHOP portfolio.”

- **RevPOR growth:** “The key assumptions that drive the midpoint of our range are average occupancy growth of about 250 basis points, RevPOR growth of about 5%, which puts the total revenue growth around 8%.”
- **\$300M pipeline:** “Our pipeline is growing as we have several interesting potential investments in our sites. Our team is actively working on transactions exceeding \$300 million that meet our criteria and I look forward to adding to that as the year progresses.”
- **Refinancing in 2024:** “So I mentioned the \$0.11 year- over-year, a big piece of that is refinancing our debt into a higher rate environment. We have \$1.2 billion of debt coming due this year, and then you call it in the mid threes kind of range from having issued that debt quite years ago. So refinancing that in the current environment is dilutive. The volume of that, also we had the year-over-year impact of ELP transaction mid year last year. So we have effectively the first half of that that we're lapping maybe -- in '24. So together those two things describe the increase year-on-year on interest expense. I'd note we've included interest expense guidance, which is new to us in order to try to help analysts model that, because I know it can be tricky, but those are the drivers.”
- **Occupancy pick up:** “We had acceleration of move-ins and occupancy in the third quarter, which led to solid growth in the fourth quarter, which was at 170 basis points year-over-year. In January, we're already starting at 200 basis points of occupancy year-over-year, and we are seeing better-than-typical seasonal results ending the fourth quarter and starting the year so far, which is really encouraging and supportive of the 250 basis points at the midpoint that were included in our SHOP guidance.”

## MPW – key quotes from the earnings call on 2/21

- **Capital allocation strategy:** “Our primary focus right now is executing a capital allocation strategy that will aim to generate at least \$2 billion of additional liquidity in 2024 and help us satisfy our debt maturities for several years into the future.”
- **Steward update:** “Unfortunately, since that time, Steward's cash collection challenges have become more pronounced and the resulting changes to vendor payment terms have put pressure on supplies, constraining Steward's ability to perform higher margin surgeries that are a key driver of cash flow. As a result, in early January, we shared that we have been working with Steward and its advisors to develop an action plan to strengthen their balance sheet, liquidity, accelerate recovery of unpaid rent, and ultimately significantly reduce our exposure to Steward. This plan contemplates a wide range of strategic transactions, including transitioning certain hospitals to new tenants and selling its managed care business called Stewardship.”
- **Bridge loan:** “As we previously disclosed in January, we funded a \$60 million bridge loan, which provided an exact MPT, a second lien on Stewardship's business subordinate only to Steward's ABL lenders. We also consented to a limited and tapering deferral of rent until the end of June or the completion of the anticipated asset sales.”
- **Financial covenants:** “We have significant headroom in our own financial covenants, either with the bank group or with the unsecured bond and interest.”
- **Additional funding to Steward:** “In the fourth quarter, Steward paid approximately 25% of all rent and interest owed to MPT. In our press release this morning, we shared that MPT and certain lenders in the ABL group are negotiating a



new bridge facility under which each party would fund an additional initial \$37.5 million to Steward, of which MPT has already funded \$20 million. Any additional funding is entirely dependent on Steward's achieving significant milestones towards optimizing the amount and timing of MPT's recoveries."

- **Prospect update:** "Turning to Prospect. Importantly, in California, Prospect is current on all rent and interest due through January 2024. Though they have not yet paid February's rent, Prospect's EBITDARM has improved year over year, driven by increased admission volumes, higher Medi-Cal reimbursement rates and lower supplies costs. We are encouraged by their most recent December trailing 12 months rent coverage, which was above one time."
- **Debt maturities:** "As we realize capital from these transactions, we expect to immediately reduce our debt maturities. In 2024, we have only two maturing loans, approximately \$300 million in May and \$130 million in December. In the interim, we will reduce our revolver balances, which in recent months have carried an interest rate of around 6.9% for the US dollar borrowings. In 2025, we will have roughly \$900 million in bank debt and \$550 million in unsecured notes maturing. And as just noted, we expect our planned sales and secured financing transactions will provide more than sufficient proceeds to satisfy these maturities."
- **Asset sales:** "During the fourth quarter, we closed on the sale of our four remaining Australian facilities for approximately \$305 million, or a 5.7% CAP rate. And in our press release earlier this morning, we announced another \$480 million of agreed upon liquidity transactions, including the sale of five hospitals to Prime at a 7.4% economic cap rate, as well as the sale of our syndicated term loan investment in MEDIAN, the parent company of Priory Group."
- **Sale to Prime:** "This morning, we announced that we have so far agreed to transactions aggregating almost 25% of that initial target. The largest of these transactions is our agreement to sell two hospitals to Prime for \$350 million. Importantly and encouragingly, the economics of the transaction imply a capitalization rate of about 7.4% that is obviously much better than what our share price implies or even what some investors believe our secured financing rate would be."

## ARE – key quotes from the earnings call on 1/30

- **Supply and TI's:** "Yeah, hard to predict, but certainly the effects of 2023's supply has been seen. Net effective rents, we've seen TI's increase remarkably. We've talked about that before. TI's aren't going to go any further up because they're already pretty high. I'd say there's some pricing power to the tenant if they've got a very large requirement. But outside of that, I think things have been holding relatively well."
- **Occupancy expectations:** "We expect same-property results to accelerate in the second half of 2024, driven by anticipated solid rental rate growth, occupancy growth in the second half of the year, coupled with the four properties I just mentioned, as well as contractual rent increases and the burn-off of contractual free rent from executed leases. We expect solid same-property growth for 2024, consistent with what we provided at our Investor Day in December, of 1.5% and 4% on a cash basis at the midpoint of our guidance range."
- **Leasing for 2024:** "we've got about 3.4 million of lease rolls next year. But after you back out the space that we've anticipated will go dark, that will go into redevelopment or development, that only leaves you with about 1.8 million square feet that's not resolved. So, I think that number feels pretty manageable relative to our historical run rate on leasing."

- **SS NOI Growth:** "We expect solid rental rate growth on lease renewals and re-leasing of space for 2024 at a midpoint of 15% and 9% on a cash basis, with some variation from quarter to quarter. The overall mark-to-market for cash rental rates in our -- related to our in-place leases for the entire asset base remains solid at 14%. Our non-revenue enhancing expenditures, including TIs and leasing commissions on second-generation space, have averaged 15% of NOI over the last five years and remained low during 2023 in the 12% to 13% range."
- **Deliveries:** "We expect tremendous growth in incremental annual net operating income on a cash basis of \$114 million upon the burn-off of initial free rent related to recently delivered projects with a weighted average burn-off period of about 10 months. And as Peter highlighted, we have 5.7 million rentable square feet of projects that are 60% leased or negotiating, and projects that will generate \$495 million of incremental annual net operating income over the next four years."
- **Demand expectations:** "We believe the beginning of 2023 was the low point for demand and are pleased to see that demand for Greater Boston, San Francisco Bay, and San Diego are all up year-over-year, a good sign, since this does not include a number of projects that are on hold as management teams and Boards remain cautious. However, that should change soon."
- **Peak deliveries in 2024:** "As we turn the page on 2023, we expect 2024 to be the peak year for new deliveries, then begin to dissipate in 2025."
- **Boston supply:** "In Greater Boston, unleased competitive supply estimated to be delivered in 2024 is 7% of market inventory, a 0.9% increase over last quarter, not due to new projects, but because of project deliveries being pushed from 2023 to 2024. In 2025, the unleased competitive supply will increase market inventory by another 2.5%, an expected slowdown from 2024 levels."
- **SF supply:** "In San Francisco Bay, unleased competitive supply estimated to be delivered in 2024 is 10.7% of market inventory, which is a 2.7% increase. Like Greater Boston, this increase was driven by projects that were expected to deliver in 2023, but are taking longer than expected. In 2025, the unleased competitive supply will increase market inventory by much less at 2.2%, a good sign, but still a 1% increase over last quarter due to a new project breaking ground in Menlo Park."
- **San Diego supply:** "In San Diego, unleased competitive supply estimated to be delivered in 2024 is 6.8% of market inventory, a slight decrease from last quarter due to an increase in supply from projects being pushed from 2023 to 2024, offset by leasing in those projects. In 2025, the unleased competitive supply will decelerate to 2.7% of market inventory."
- **Strong leasing efforts 2024:** "Two key leases in fourth quarter, which are noted in the supplement, the lease to Novo Nordisk and the lease to Cargo Therapeutics. 2023, we had a remarkable 76% of leasing with existing tenants, and we look forward to a strong 2024 leasing effort and expect a handful of significant leases to mature soon."
- **Pfizer:** "want to comment on the sale of our 42nd Street asset in New York City, leased to Pfizer through mid-year 2024. They previously vacated and moved their headquarters to another site in New York City. We made a strategic decision not to go forward with the contemplated redevelopment of that building, due in part to state and local -- to challenging state and local governmental policies."
- **M&A lifecycle:** "Another 2023 biopharma trend was M&A. Excluding mega-mergers over \$50 billion, 2023 set a new high watermark, with \$159 billion in acquisitions. These were largely sub-\$10 billion deals, driven by pharma's need to bolster





pipelines, as they face steep revenue loss due to patent expirations. As M&A dollars are recycled back into the industry, it creates a positive cycle of innovation as scientists and entrepreneurs start their next new venture. Altogether, the M&A lifecycle is an important driver of demand across our regions."

## PEAK- key quotes from the earnings call on 2/9

- **MOB supply/demand** "I want to share some thoughts on the operating environment for the two largest segments, starting with Outpatient Medical, where the sector is benefiting from demand exceeding supply. We have two decades of operating history in the sector and in 2023, we were at or near all-time highs for leasing volume, retention, renewal spreads, and same-store growth."
- **Life Science outlook:** "Let me turn to our Lab business. The fundamental drivers of long-term growth are solidly intact with both drug approvals and new drug applications at or near all-time highs. That means R&D funding is paying dividends, creating a virtuous cycle. Big Pharma is ramping up partnership deals and M&A to replace looming patent expirations, and companies with good data have ready access to capital. At the same time, venture capital deployment and the IPO market remain soft and Boards are deferring leasing decisions when possible. Those dynamics will eventually turn in our favor and we'll be well-positioned to capitalize."
- **Delivery reduction in 2025:** "We can also comfortably underwrite a massive reduction in new deliveries starting in 2025. Fortunately, even during the market exuberance for life science, we stuck to our strategy. As a result, we're highly concentrated in five of the best submarkets in the country, where we have significant scale and deep relationships to capture leasing demand."
- **FFO guidance:** "With all that said, our initial outlook for 2024 is as follows. FFO as adjusted ranging from \$1.73 to \$1.79 per share, which includes merger-related benefits of approximately \$0.02 to \$0.03, AFFO ranging from \$1.50 to \$1.56 per share, which includes merger-related benefits of approximately \$0.05, and total same-store growth ranging from positive 2.25% to positive 3.75%."
- **DOC merger:** "First, based on the March 1st closing date, our outlook is for two months, standalone Healthpeak, and 10 months combined Healthpeak and DOC. The result of this is a weighted average share count of approximately 690 million for full-year 2024, assuming no additional equity issuances. Second, we have identified sources for all of our capital needs and have no remaining funding requirement in 2024. We upsized our five-year term loan to \$750 million and recently swapped the entire amount to a fixed rate of 4.5%."
- **Callan Ridge JV:** "Last month, we closed on our well-received Callan Ridge joint venture, generating \$130 million of proceeds and eliminating \$22 million of future TI spend. We have \$250 million of projected retained earnings given our well-covered dividend and we expect some seller financing debt repayments. These proceeds will be used to fund our development and redevelopment pipeline, repay \$210 million of DOC's private placement notes, and fund all of our transaction costs."
- **G&A Guidance:** "G&A is expected to range from \$95 million to \$105 million, which compares to standalone peak at approximately \$95 million for full-year 2023. All in, our G&A is only increasing by approximately \$5 million at the midpoint, despite inflation and our asset base increasing by \$5 billion."
- **Debt mark to Market:** "our current FFO outlook includes a negative \$0.03 mark-to-market on the \$1.9 billion of DOC debt that we will assume. Notably, we do not add back this headwind to FFO as adjusted....we do not include any benefit from the Graphite Bio termination fee in our FFO as adjusted."



- **Same-Store growth outlook:** "We see Outpatient Medical ranging from positive 2.5% to positive 3.5%. Fundamentals in Outpatient Medical continue to improve versus historical norms, including higher tenant retention, increased rent mark-to-market, and increased escalators. Our Outpatient Medical same-store NOI for 2024 is approximately \$825 million or 60% of the overall pool. We have included the DOC portfolio in our same-store pool for 2024, given the size and strategic nature of the merger."
- **Lab same-store growth:** "We see same-store growth ranging from positive 1.5% to positive 3%. Lab growth is driven by contractual rent escalators, positive rent mark-to-market, and the benefit of increased NOI from internalizing operations in San Francisco and San Diego. Not surprising, we do have some offsets, including a modest decline in occupancy relative to 2023, and timing of free rent, which naturally fluctuates year-to-year and is a headwind, particularly in the first quarter."
- **Developments pushed out:** "I can certainly start with that and I'll hit on the biggest ones. Vantage, we actually delivered a portion of that late last year. And then the initial occupancy is for what's remaining and we do have another lease with Astellas that's expected to start later this year. So that's really the reason why that got pushed back a little bit, it's because we delivered a portion of that."
- **Sorrento and Amgen:** "So just on Amgen, Sorrento, and Vantage alone, you're talking about \$50 million, \$60 million of NOI upside. I don't know if that's '25 or '26, but we do think it's achievable. Those are all Class A assets. Now, there's a cost of capital, so maybe subtract a little bit of that upside from an earnings standpoint, but it's substantial. So our Lab business two years ago was kind of at full utilization, for lack of a better word, and today, there's a fair amount of upside for us to go recapture."
- **MOB growth expectation:** "I mean, it's really been a 2% to 3% growth business for the last decade, we do see that accelerating. It's not going to 10%, but we do think it's going to improve for the forward 5 to 10 years versus the previous 5 to 10 years, just given supply demand construction costs and therefore, our ability to push rents. So our guidance this year is at the very high end -- actually well above the high end of any guidance we've given in that segment historically. And we have a pretty good track record of beating our same-store guidance and our earnings guidance."
- **MOB occupancy expectations:** "We're at 85% occupancy today. I would think we could get back into the 90s. In that portfolio, it's performing well."
- **Escalators:** "But I think we said historically, DOC has lower in place escalators in Healthpeak, but that's converging over time as they sign new leases with, as John said, 3% or better escalator. So I'm guessing it'd be a little bit lower, but not materially. I think they said numerous times their growth rate in 2023 was impacted by some unique asset specific events and proactive termination. So I would expect their growth rate to mirror or closely mirror the Healthpeak growth rate going forward."
- **Occupancy growth:** "Well, we still see some occupancy growth in 2024. Rental rates will grow, but more in the mid single-digits as opposed to high single-digits, just given the fundamentals in that sector. Then obviously, we've had a huge benefit from contract labor coming down. Over the past 18 months, we're largely through that benefit. We have very little contract labor in the portfolio today. So you just lose a lot of that benefit in same-store. So I mean, that's what's happening at the property level."



## OHI- key quotes from the earnings call on 2/8


- **Leverage update:** "As of year end 99% of our \$5.1 billion in debt was at fixed rates, and our net funded debt to annualized adjusted normalized EBITDA was 4.96 times and our fixed-charge coverage ratio was 3.8 times."
- **2024 guidance:** "for the first time since the start of the pandemic, we are providing full year adjusted FFO guidance of between \$2.70 to \$2.80 per share. We're assuming no change in our revenue related to operators currently on an accrual basis of revenue recognition or stated another way, no additional operators being placed on a cash basis for revenue recognition. We're assuming a timely completion of operator restructurings, which includes both the LaVie and Guardian portfolios and Maplewood's eventual return to full contractual rent. We're assuming \$94 million in asset sales, related to the facilities classified as held-for-sale as of year end. We've included the annual impact of new investments completed in 2023, as well as \$27 million of new investments completed year-to-date."
- **Lavie and Guardian:** "As stated in yesterday's earnings press release, in the fourth quarter, LaVie paid \$5.3 million in rent, and in January, LaVie paid approximately \$1.45 million in rent. We utilized Guardian's \$4.4 million security deposit to record fourth quarter rent. The remaining \$60,000 in security deposit was exhausted in January and no additional cash rent was received from Guardian in January."
- **Occupancy:** "Occupancy for our overall core portfolio has continued to recover from a low of 74.6% in January of 2022 to 80.2% as of mid-January 2024 based upon preliminary reporting from our operators. For comparative purposes, occupancy for our core portfolio was 83.2% for the fourth quarter of 2019, just prior to the onset of the COVID pandemic."
- **Acquisition cash yield:** "So most of the yields that we're underwriting, too, are 10% or even north. All the fourth quarter yields on those investments that you highlighted were 9%. Some of those deals were a long time in the making that's been in the pipeline for a while. So we had quoted a price some quarters back. The overall yield for the year is north of 10%. I think it's 10.4% blended, so. And that's pretty much what we're quoting today, is 10% in north."
- **Full rent assumption:** "we return to happily so our adjusted FFO guidance based on historical practices and gave a little bit wider range because we did mention we have LaVie and Guardian in the transition restructuring mode, and Maplewood needs to return to paying full contractual rent. So at the low end, it means it takes a little bit longer on those transactions and the repayment. And at the high end, it's just sooner. I mean, it's kind of that simple."
- **Maplewood rent escalators:** "the January cash is a good run rate to start, but it doesn't reflect the impact of rate increases for '24, which the Maplewood team expects to be 7% to 8% net. So that's -- we'll see a pickup there as we start to march through the early part of the year, [ph]pick room."
- **Occupancy and staffing increase:** "I think, what we're hearing from our operators is mostly the fact that the staffing is easing up. Right. Some of the agencies has come down. They're getting more permanent staff in. They're building up their cultures again, and it's just easier to have staff in the building and increase that occupancy. That's really what's driving it."
- **Investment pipeline and yield:** "I will say that we are seeing a very active pipeline at this point, where I've been as active since -- before the start of COVID. So we are, as we pointed out, seeing a number of loan requests, but we're sort of able to pick and choose the right deals, and we are able to -- we are holding pretty firm on our 10% yield requirements."

- **Dividend coverage:** " So based on the assumptions in the forecast, I would assume that that's going to run anywhere from \$0.02 to \$0.04 less per in -- per quarter based on AFFO guides, and there's a possibility based on given the range and what we see, but really timing is unknown, that we could, on a run rate basis, cover the dividend in the late second quarter. But again, timing is the key there."

## Leverage

### Exhibit 2: Reported leverage metrics

Reported leverage metrics



Company Filings

WELL & SBRA: Net Debt to Adjusted EBITDA; ARE: Net debt and preferred stock to Annualized Adjusted EBITDA; DOC: Net Consolidated Debt to Consolidated Adjusted EBITDA; MPW: Adjusted Net Debt to Annualized EBITDA; OHI: Net Funded Debt to Adjusted Normalized EBITDA; PEAK: Net Debt to Adjusted EBITDA; VTR: Net Debt to Adjusted Pro Forma EBITDA

BofA GLOBAL RESEARCH

## PO & Estimate changes

### Exhibit 3: Summary of AFFO estimate changes

Updated published estimates after review of models

Ticker	2023		2024		2025		2026		2027	
	Old	New	Old	New	Old	New	Old	New	Old	New
VTR	\$2.31	\$2.31	\$2.52	\$2.44	\$2.80	\$2.57	\$3.22	\$2.79	\$3.72	\$2.96
MPW	\$1.28	\$1.30	\$1.21	\$0.86	\$1.26	\$0.96	\$1.09	\$0.84	\$0.97	\$0.73

Source: BofA Global Research

BofA GLOBAL RESEARCH

### Exhibit 4: Summary of PO changes

Updated price objective after review of models

Ticker	Old PO	New PO	QRQ	Price
VTR	\$53.00	\$49.00	B-1-7	\$44.16
MPW	\$5.00	\$4.05	C-3-8	\$3.84

Source: BofA Global Research, prices as of 2/23/2024

BofA GLOBAL RESEARCH

- VTR (B-1-7): After updating our model for 4Q23 earnings and 2024 guide, we are lowering our PO to \$49 from \$53. We derive our PO from applying a AFFO multiple of 20x (previously 20.5x) to our 2024 AFFO estimate of \$2.44 (previously \$2.52). We believe the multiple is warranted given current market conditions.
- MPW (C-3-8): After updating for 4Q23 earnings, we are lowering our PO for MPW to \$4.05 (previously \$5.00). Our PO trades in line with our forward NAV of \$3.70. We derive our NAV by applying a 9.5% (unchanged) cap rate to our forward NOI of \$991M.

**Exhibit 5: Companies Mentioned**

These are the REITs mentioned in this report

<b>Ticker</b>	<b>PO</b>	<b>Rating</b>	<b>QRQ</b>	<b>Price</b>
ARE	130.00	BUY	B-1-7	\$121.93
WELL	96.00	BUY	B-1-7	\$93.41
MPW	4.05	UNDERPERFORM	C-3-8	\$3.84
OHI	31.00	NEUTRAL	B-2-8	\$31.12
PEAK	18.00	UNDERPERFORM	B-3-7	\$16.63
SBRA	16.00	BUY	B-1-7	\$13.97
VTR	49.00	BUY	B-1-7	\$44.16

**Source:** BofA Global Research, prices as of 2/23/2024

BofA GLOBAL RESEARCH

## Key terms:

---

ABL: Asset based lending

EBITDAR: earnings before interest, taxes, depreciation, amortization, and rent

EBITDARM: earnings before interest, taxes, depreciation, amortization, rent and management fees.

ExPOR: Expense per occupied bed

FFOAA: Funds from operations as adjusted

HC: Healthcare

MOB: Medical office building

NOI: Net Operating Income

LS: Life Science

REVPOR: Revenue per occupied bed

RIDEA: REIT Investment Diversification and Empowerment

SHOP: senior housing operating portfolio

SS: same store

SH: senior housing

SNF: skilled nursing facilities

US: United States



## Price objective basis & risk

### Alexandria Real Estate Equities (ARE)

Our \$130 price objective for ARE is derived from a 10% discount to our forward NAV to reflect the strength of ARE's platform in the life sciences real estate sector. We apply a 6.7% cap rate to our forward NOI estimate of \$2.5B to calculate our NAV. We use a 6.7% cap rate for ARE based on our view of interest rates over the next year, comparable transaction comps, and the market exposure of ARE. Upside risks to our PO are capital raises, operating conditions and development yields above our expectations. Downside risks are operating conditions and yields below our expectations. ARE is also exposed to the risks of the biotech sector such as private and public funding, regulatory changes and the FDA approval process. Further, a prolonged period of tight credit market conditions could weigh on access to capital, borrowing costs, and direct real estate values.

### Healthpeak Properties, Inc. (PEAK)

Our \$18 price objective assumes the stock trades at a 20% discount to our forward NAV estimate. We apply a 7.4% cap rate to our forward NOI estimate of \$1.8B. We use a 7.4% cap rate for PEAK based on our view of interest rates over the next year, current private market/transaction comps, and the market exposure of PEAK. We also apply a 20% discount to our forward NAV estimate to account for a tenant that filed for bankruptcy. Upside risks to our PO are better-than-expected senior housing, medical office or life science performance, higher-than-forecast acquisition volumes and lower interest rates. Downside risks to our PO are further public-pay reimbursement cuts, a more competitive acquisitions environment, weaker-than-expected senior housing fundamentals, increased tenant credit risk, and rising interest rates.

### Medical Properties Trust, Inc. (MPW)

Our \$4.05 PO trades in line with our forward NAV estimate of \$3.70. We derive our NAV estimate by applying a 9.5% cap rate to our forward NOI estimate of \$991.1m. We use a 9.5% cap rate based on our outlook for interest rates and current market/transaction comps. Risks to our price objective are more or fewer acquisitions, acquisition cap rates vs MPW's cost of capital, tenant issues including potential bankruptcies, and changes in the healthcare market that makes hospitals more or less profitable.

### OMEGA Healthcare (OHI)

Our \$31 price objective for OHI is derived by applying an adjusted funds from operations (AFFO) multiple to our 2024 forward AFFO estimate. We use a target AFFO multiple of 12.0x to our 2024 AFFO estimate, to be slightly above OHI's historical average of 11x.

Risks to our price objective are increased government reimbursement pressure, better-/weaker-than-expected SNF demand from the aging of America, operator issues may rise again, volume/pricing of acquisition opportunities, and more / less government support. The pace of occupancy recovery post COVID is also a key risk.

### Sabra Health Care (SBRA)

Our \$16.00 price objective for SBRA is derived by applying a 11.0x AFFO multiple to forward 2023 AFFO estimate as we look to earnings growth beyond 2022. We believe a 11.0x AFFO multiple is more consistent with SBRA's recent historical AFFO multiple which we think it deserves due to its similar growth rate. Upside and downside risks to our price objective are more / less acquisition, cap rates vs. SBRA's cost of capital, shifting industry trends, demand vs. supply for senior housing assets and interest rates.

### Ventas, Inc. (VTR)

Our \$49 price objective is derived by applying an AFFO multiple to our 2024 forward AFFO estimate as we look to a more normalized earnings period. We apply a target

AFFO multiple of 20x, which reflects the current market conditions.

Upside risks to our price objective are better-than-expected senior housing fundamentals, declining interest rates, and lower tenant risk.

Downside risks to our price objective are weaker-than-expected senior housing fundamentals, increased tenant credit risk, and rising interest rates

### **Welltower (WELL)**

Our \$96 price objective for WELL is now derived by applying a AFFO Multiple to our 2024 forward AFFO estimate as we look to a more normalized earnings period. We use a target AFFO multiple of 26.5x and we believe this is warranted given: (1) depressed earnings due to the COVID pandemic, (2) our expectations of a multi-year period of above average earnings growth driven by a rebound in senior housing as the COVID pandemic fades. Upside risks to our PO are better-than-expected senior housing or medical office building performance, higher-than-forecast dividend growth and lower interest rates. Downside risks to our PO are further public-pay reimbursement cuts, a more competitive acquisitions environment, weaker-than-expected senior housing fundamentals, increased tenant credit risk, and rising interest rates.

## **Analyst Certification**

We, Joshua Dennerlein and Jeffrey Spector, hereby certify that the views each of us has expressed in this research report accurately reflect each of our respective personal views about the subject securities and issuers. We also certify that no part of our respective compensation was, is, or will be, directly or indirectly, related to the specific recommendations or view expressed in this research report.

## **Special Disclosures**

BofA Securities is currently acting as financial advisor to Physicians Realty Trust in connection with its proposed merger of equals with Healthpeak Properties Inc., which was announced on October 30, 2023. The proposed transaction is subject to approval by shareholders of Physicians Realty Trust and Healthpeak Properties Inc. This research report is not intended to provide voting advice, serve as an endorsement of the proposed transaction, or result in the procurement, withholding or revocation of a proxy.



## US - REITs Coverage Cluster

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
<b>BUY</b>				
	Agree Realty Corp	ADC	ADC US	Joshua Dennerlein
	Alexandria Real Estate Equities	ARE	ARE US	Joshua Dennerlein
	American Homes 4 Rent	AMH	AMH US	Jeffrey Spector
	Americold Realty Trust	COLD	COLD US	Joshua Dennerlein
	AvalonBay Communities Inc	AVB	AVB US	Joshua Dennerlein
	Boston Properties	BXP	BXP US	Jeffrey Spector
	Brixmor Property Group	BRX	BRX US	Jeffrey Spector
	COPT Defense Properties	CDP	CDP US	Camille Bonnel
	Cousins Properties Inc.	CUZ	CUZ US	Camille Bonnel
	EastGroup Properties	EGP	EGP US	Jeffrey Spector
	Empire State Realty Trust	ESRT	ESRT US	Camille Bonnel
	Equity Residential	EQR	EQR US	Jeffrey Spector
	Essential Properties	EPRT	EPRT US	Joshua Dennerlein
	Federal Realty	FRT	FRT US	Jeffrey Spector
	Invitation Homes Inc	INVH	INVH US	Joshua Dennerlein
	Kimco Realty	KIM	KIM US	Jeffrey Spector
	Kite Realty Group	KRG	KRG US	Jeffrey Spector
	Phillips Edison & Company	PECO	PECO US	Jeffrey Spector
	Prologis, Inc.	PLD	PLD US	Camille Bonnel
	Public Storage, Inc.	PSA	PSA US	Jeffrey Spector
	Regency	REG	REG US	Jeffrey Spector
	Rexford Industrial Realty	REXR	REXR US	Camille Bonnel
	Sabra Health Care	SBRA	SBRA US	Joshua Dennerlein
	Simon Property	SPG	SPG US	Jeffrey Spector
	Ventas, Inc.	VTR	VTR US	Jeffrey Spector
	Welltower	WELL	WELL US	Joshua Dennerlein
<b>NEUTRAL</b>				
	Acadia Realty Trust	AKR	AKR US	Jeffrey Spector
	CubeSmart	CUBE	CUBE US	Jeffrey Spector
	EPR Properties	EPR	EPR US	Joshua Dennerlein
	Equity LifeStyle Properties	ELS	ELS US	Jeffrey Spector
	Essex Property Trust, Inc.	ESS	ESS US	Joshua Dennerlein
	Extra Space Storage, Inc.	EXR	EXR US	Jeffrey Spector
	Getty Realty Corp.	GTY	GTY US	Joshua Dennerlein
	Highwoods Properties	HIW	HIW US	Camille Bonnel
	InvenTrust Properties	IVT	IVT US	Jeffrey Spector
	Kilroy Realty Corporation	KRC	KRC US	Camille Bonnel
	Macerich	MAC	MAC US	Jeffrey Spector
	OMEGA Healthcare	OHI	OHI US	Joshua Dennerlein
	Realty Income	O	O US	Jeffrey Spector
	Retail Opportunity Investments Corp.	ROIC	ROIC US	Jeffrey Spector
	SL Green Realty	SLG	SLG US	Camille Bonnel
	Sun Communities	SUI	SUI US	Joshua Dennerlein
	UDR, Inc.	UDR	UDR US	Joshua Dennerlein
	Veris Residential Inc	VRE	VRE US	Joshua Dennerlein
	Vornado Realty	VNO	VNO US	Camille Bonnel
<b>UNDERPERFORM</b>				
	American Assets Trust	AAT	AAT US	Camille Bonnel
	Armada Hoffer Properties	AHH	AHH US	Camille Bonnel
	Camden Property Trust	CPT	CPT US	Joshua Dennerlein
	Douglas Emmett	DEI	DEI US	Camille Bonnel
	Healthpeak Properties, Inc.	PEAK	PEAK US	Joshua Dennerlein
	Hudson Pacific Properties, Inc.	HPP	HPP US	Camille Bonnel
	Kennedy Wilson	KW	KW US	Joshua Dennerlein
	LXP Industrial Trust	LXP	LXP US	Camille Bonnel
	Medical Properties Trust, Inc.	MPW	MPW US	Joshua Dennerlein
	Mid-America Apartment Communities, Inc.	MAA	MAA US	Joshua Dennerlein
	National Storage Affiliates Trust	NSA	NSA US	Jeffrey Spector
	NetSTREIT	NTST	NTST US	Joshua Dennerlein
	NNN REIT Inc	NNN	NNN US	Joshua Dennerlein
	Paramount Group	PGRE	PGRE US	Camille Bonnel
	Peakstone Realty Trust	PKST	PKST US	Joshua Dennerlein
	STAG Industrial	STAG	STAG US	Camille Bonnel

## US - REITs Coverage Cluster

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
	Tanger Inc	SKT	SKT US	Jeffrey Spector
	WP Carey	WPC	WPC US	Joshua Dennerlein

# Disclosures

## Important Disclosures

## Equity Investment Rating Distribution: REITs (Real Estate Investment Trusts) Group (as of 31 Dec 2023)

Coverage Universe	Count	Percent	Inv. Banking Relationships <sup>R1</sup>	Count	Percent
Buy	40	46.51%	Buy	33	82.50%
Hold	27	31.40%	Hold	21	77.78%
Sell	19	22.09%	Sell	16	84.21%

## Equity Investment Rating Distribution: Global Group (as of 31 Dec 2023)

Coverage Universe	Count	Percent	Inv. Banking Relationships <sup>R1</sup>	Count	Percent
Buy	1895	53.62%	Buy	1083	57.15%
Hold	832	23.54%	Hold	454	54.57%
Sell	807	22.84%	Sell	383	47.46%

<sup>R1</sup> Issuers that were investment banking clients of BofA Securities or one of its affiliates within the past 12 months. For purposes of this Investment Rating Distribution, the coverage universe includes only stocks. A stock rated Neutral is included as a Hold, and a stock rated Underperform is included as a Sell.

**FUNDAMENTAL EQUITY OPINION KEY:** Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. **VOLATILITY RISK RATINGS**, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. **INVESTMENT RATINGS** reflect the analyst's assessment of both a stock's absolute total return potential as well as its attractiveness for investment relative to other stocks within its Coverage Cluster (defined below). Our investment ratings are: 1 - Buy stocks are expected to have a total return of at least 10% and are the most attractive stocks in the coverage cluster; 2 - Neutral stocks are expected to remain flat or increase in value and are less attractive than Buy rated stocks and 3 - Underperform stocks are the least attractive stocks in a coverage cluster. An investment rating of 6 (No Rating) indicates that a stock is no longer trading on the basis of fundamentals. Analysts assign investment ratings considering, among other things, the 0-12 month total return expectation for a stock and the firm's guidelines for ratings dispersions (shown in the table below). The current price objective for a stock should be referenced to better understand the total return expectation at any given time. The price objective reflects the analyst's view of the potential price appreciation (depreciation).

Investment rating	Total return expectation (within 12-month period of date of initial rating)	Ratings dispersion guidelines for coverage cluster <sup>R2</sup>
Buy	≥ 10%	≤ 70%
Neutral	≥ 0%	≤ 30%
Underperform	N/A	≥ 20%

<sup>R2</sup> Ratings dispersions may vary from time to time where BofA Global Research believes it better reflects the investment prospects of stocks in a Coverage Cluster.

**INCOME RATINGS**, indicators of potential cash dividends, are: 7 - same/higher (dividend considered to be secure), 8 - same/lower (dividend not considered to be secure) and 9 - pays no cash dividend. **Coverage Cluster** is comprised of stocks covered by a single analyst or two or more analysts sharing a common industry, sector, region or other classification(s). A stock's coverage cluster is included in the most recent BofA Global Research report referencing the stock.

Price Charts for the securities referenced in this research report are available on the [Price Charts website](#), or call 1-800-MERRILL to have them mailed.

BofAS or one of its affiliates acts as a market maker for the equity securities recommended in the report: Alexandria, Healthpeak Prop., Medical Prop Trust, OMEGA Healthcare, Sabra Health Care, Ventas Inc., Welltower.

BofAS or an affiliate was a manager of a public offering of securities of this issuer within the last 12 months: Alexandria, Ventas Inc., Welltower.

The issuer is or was, within the last 12 months, an investment banking client of BofAS and/or one or more of its affiliates: Alexandria, Healthpeak Prop., Medical Prop Trust, OMEGA Healthcare, Sabra Health Care, Ventas Inc., Welltower.

BofAS or an affiliate has received compensation from the issuer for non-investment banking services or products within the past 12 months: Alexandria, Healthpeak Prop., Medical Prop Trust, OMEGA Healthcare, Sabra Health Care, Ventas Inc., Welltower.

The issuer is or was, within the last 12 months, a non-securities business client of BofAS and/or one or more of its affiliates: Alexandria, Healthpeak Prop., Medical Prop Trust, OMEGA Healthcare, Sabra Health Care, Ventas Inc., Welltower.

BofAS or an affiliate has received compensation for investment banking services from this issuer within the past 12 months: Alexandria, Healthpeak Prop., Medical Prop Trust, OMEGA Healthcare, Sabra Health Care, Ventas Inc., Welltower.

BofAS or an affiliate expects to receive or intends to seek compensation for investment banking services from this issuer or an affiliate of the issuer within the next three months: Alexandria, Healthpeak Prop., Medical Prop Trust, Sabra Health Care, Ventas Inc., Welltower.

BofAS together with its affiliates beneficially owns one percent or more of the common stock of this issuer. If this report was issued on or after the 9th day of the month, it reflects the ownership position on the last day of the previous month. Reports issued before the 9th day of a month reflect the ownership position at the end of the second month preceding the date of the report: Sabra Health Care, Welltower.

BofAS or one of its affiliates is willing to sell to, or buy from, clients the common equity of the issuer on a principal basis: Alexandria, Healthpeak Prop., Medical Prop Trust, OMEGA Healthcare, Sabra Health Care, Ventas Inc., Welltower.

The issuer is or was, within the last 12 months, a securities business client (non-investment banking) of BofAS and/or one or more of its affiliates: Alexandria, Healthpeak Prop., Medical Prop Trust, OMEGA Healthcare, Sabra Health Care, Ventas Inc., Welltower.

BofA Global Research personnel (including the analyst(s) responsible for this report) receive compensation based upon, among other factors, the overall profitability of Bank of America Corporation, including profits derived from investment banking. The analyst(s) responsible for this report may also receive compensation based upon, among other factors, the overall profitability of the Bank's sales and trading businesses relating to the class of securities or financial instruments for which such analyst is responsible.



## Other Important Disclosures

From time to time research analysts conduct site visits of covered issuers. BofA Global Research policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits.

Prices are indicative and for information purposes only. Except as otherwise stated in the report, for any recommendation in relation to an equity security, the price referenced is the publicly traded price of the security as of close of business on the day prior to the date of the report or, if the report is published during intraday trading, the price referenced is indicative of the traded price as of the date and time of the report and in relation to a debt security (including equity preferred and CDS), prices are indicative as of the date and time of the report and are from various sources including BofA Securities trading desks.

The date and time of completion of the production of any recommendation in this report shall be the date and time of dissemination of this report as recorded in the report timestamp.

Recipients who are not institutional investors or market professionals should seek the advice of their independent financial advisor before considering information in this report in connection with any investment decision, or for a necessary explanation of its contents.

Officers of BofAS or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments.

Refer to [BofA Global Research policies relating to conflicts of interest](#).

**"BofA Securities" includes BofA Securities, Inc. ("BofAS") and its affiliates. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. "BofA Securities" is a global brand for BofA Global Research.**

### Information relating to Non-US affiliates of BofA Securities and Distribution of Affiliate Research Reports:

BofAS and/or Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") may in the future distribute, information of the following non-US affiliates in the US (short name: legal name, regulator): Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd., regulated by The Financial Service Board; MLI (UK): Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers (AMF). BofA Securities Europe SA ("BofASE") with registered address at 51, rue La Boétie, 75008 Paris is registered under no 842 602 690 RCS Paris. In accordance with the provisions of French Code Monétaire et Financier (Monetary and Financial Code), BofASE is an établissement de crédit et d'investissement (credit and investment institution) that is authorised and supervised by the European Central Bank and the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers. BofASE's share capital can be found at [www.bofam.com/BofASEdisclaimer](http://www.bofam.com/BofASEdisclaimer); BofA Europe (Milan): Bank of America Europe Designated Activity Company, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI); BofA Europe (Frankfurt): Bank of America Europe Designated Activity Company, Frankfurt Branch regulated by BaFin, the ECB and the CBI; BofA Europe (Madrid): Bank of America Europe Designated Activity Company, Sucursal en España, regulated by the Bank of Spain, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch Equities (Australia) Limited, regulated by the Australian Securities and Investments Commission; Merrill Lynch (Hong Kong): Merrill Lynch (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSF); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch Canada Inc, regulated by the Canadian Investment Regulatory Organization; Merrill Lynch (Mexico): Merrill Lynch Mexico, SA de CV, Casa de Bolsa, regulated by the Comisión Nacional Bancaria y de Valores; Merrill Lynch (Argentina): Merrill Lynch Argentina SA, regulated by Comisión Nacional de Valores; BofAS Japan: BofA Securities Japan Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; BofAS India: BofA Securities India Limited, regulated by the Securities and Exchange Board of India (SEBI); Merrill Lynch (Israel): Merrill Lynch Israel Limited, regulated by Israel Securities Authority; Merrill Lynch (DIFC): Merrill Lynch International (DIFC Branch), regulated by the Dubai Financial Services Authority (DFSA); Merrill Lynch (Brazil): Merrill Lynch S.A. Corretora de Títulos e Valores Mobiliários, regulated by Comissão de Valores Mobiliários; Merrill Lynch KSA Company: Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority.

This information has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA - details about the extent of our regulation by the FCA and PRA are available from us on request; has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by BofAS Japan, a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and distributed in Hong Kong by Merrill Lynch (Hong Kong) which is regulated by HKSF; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in India by BofAS India; and is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distributes this information in Australia only to 'Wholesale' clients as defined by s.761G of the Corporations Act 2001. With the exception of Bank of America N.A., Australia Branch, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this information in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and regulated by the DFSA. Information prepared and issued by Merrill Lynch (DIFC) is done so in accordance with the requirements of the DFSA conduct of business rules. BofA Europe (Frankfurt) distributes this information in Germany and is regulated by BaFin, the ECB and the CBI. BofA Securities entities, including BofA Europe and BofASE (France), may outsource/delegate the marketing and/or provision of certain research services or aspects of research services to other branches or members of the BofA Securities group. You may be contacted by a different BofA Securities entity acting for and on behalf of your service provider where permitted by applicable law. This does not change your service provider. Please refer to the [Electronic Communications Disclaimers](#) for further information.

This information has been prepared and issued by BofAS and/or one or more of its non-US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&S is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&S clients in the US by its non-US affiliates. Any US person receiving this information and wishing to effect any transaction in any security discussed herein should do so through BofAS and/or MLPF&S and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information. For clients that are not accredited investors, expert investors or institutional investors Merrill Lynch (Singapore) Pte Ltd accepts full responsibility for the contents of this information distributed to such clients in Singapore.

### General Investment Related Disclosures:

Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofA Securities. This document provides general information only, and has been prepared for, and is intended for general distribution to, BofA Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific person(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.

Securities and other financial instruments referred to herein, or recommended, offered or sold by BofA Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. Digital assets are extremely speculative, volatile and are largely unregulated. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or

financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

This report may contain a short-term trading idea or recommendation, which highlights a specific near-term catalyst or event impacting the issuer or the market that is anticipated to have a short-term price impact on the equity securities of the issuer. Short-term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short-term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.

BofA Securities is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to "short" securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting "shortselling" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned herein. Investors in such securities and instruments, including ADRs, effectively assume currency risk.

BofAS or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. BofAS or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

BofA Securities, through business units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information.

In the event that the recipient received this information pursuant to a contract between the recipient and BofAS for the provision of research services for a separate fee, and in connection therewith BofAS may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofAS has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by BofAS). If such recipient uses the services of BofAS in connection with the sale or purchase of a security referred to herein, BofAS may act as principal for its own account or as agent for another person. BofAS is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities referred to herein.

#### **BofA ESGMeter Methodology:**

ESGMeter is a proprietary metric based on quantitative analysis and fundamental analyst inputs that reflects our assessment of a company's Environmental, Social and Governance-related attributes. The ESGMeter is intended to indicate a company's likelihood of experiencing stronger financial stability (higher return on equity and lower earnings and price volatility) over the next three years relative to peer group. There are three ESGMeter levels - Low, Medium, and High - which indicate whether a company has attributes most likely to translate into superior financial stability (in the case of a High level) or weaker financial stability (in the case of a Low level) over the next three years relative to its peer group. A Medium level suggests that a company exhibits ESG characteristics that are likely associated with financial stability results in line with its peer group over the next three years. Full details of our methodology, financial stability definition and disclaimers are available at [BofA ESGMeter methodology](#). ESGMeter is not indicative of a company's future stock price performance and is not an investment recommendation or rating.

ESGMeter is independent of the BofA Global Research fundamental equity analyst's investment rating, volatility risk rating, income rating or price objective for that company.

#### **Copyright and General Information:**

Copyright 2024 Bank of America Corporation. All rights reserved. iQDatabase® is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly-available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities.

Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving issuers mentioned in this material is based on public information. Facts and views presented in this material that relate to any such proceedings have not been reviewed by, discussed with, and may not reflect information known to, professionals in other business areas of BofA Securities in connection with the legal proceedings or matters relevant to such proceedings.

This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofAS or any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third-party websites. BofA Securities is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.

Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and BofA Securities policy-related restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.

Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.

In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofAS or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.

## Research Analysts

---

**Jeffrey Spector**

Research Analyst  
BofAS  
+1 646 855 1363  
[jeff.spector@bofa.com](mailto:jeff.spector@bofa.com)

**Joshua Dennerlein**

Research Analyst  
BofAS  
+1 646 855 1681  
[joshua.dennerlein@bofa.com](mailto:joshua.dennerlein@bofa.com)

**Camille Bonnel >>**

Research Analyst  
Merrill Lynch (Canada)  
+1 646 855 5042  
[camille.bonnel@bofa.com](mailto:camille.bonnel@bofa.com)

**Lizzy Doykan**

Research Analyst  
BofAS  
+1 713 705 1584  
[lizzy.doykan@bofa.com](mailto:lizzy.doykan@bofa.com)

**Daniel Byun**

Research Analyst  
BofAS  
+1 646 855 3195  
[daniel.byun@bofa.com](mailto:daniel.byun@bofa.com)

**Steven Song**

Research Analyst  
BofAS  
+1 646 855 0049  
[huainan.song@bofa.com](mailto:huainan.song@bofa.com)

**Andrew Berger**

Research Analyst  
BofAS  
+1 646 855 1589  
[andrew.berger2@bofa.com](mailto:andrew.berger2@bofa.com)

**Farrell Granath**

Research Analyst  
BofAS  
+1 646 855 1351  
[farrell.granath@bofa.com](mailto:farrell.granath@bofa.com)

**REITs Team**

>> Employed by a non-US affiliate of BofAS and is not registered/qualified as a research analyst under the FINRA rules.  
Refer to "Other Important Disclosures" for information on certain BofA Securities entities that take responsibility for the information herein in particular jurisdictions.